FLG and interstitial lung disease: Higher frequency or higher level, respectively, of anti-filaggrin antibodies [Fil307–324 (CCP1)] and of anti-enolase 1A cyclic and anti-CEP1 antibodies showed significant associations in each of the two studies with the outcome measure, PF and ILD, respectively.